Literature DB >> 11587987

Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease.

M Dahl1, A Tybjaerg-Hansen, J Vestbo, P Lange, B G Nordestgaard.   

Abstract

We tested whether increased concentrations of the acute-phase reactant fibrinogen correlate with pulmonary function and rate of chronic obstructive pulmonary disease (COPD) hospitalization. We measured plasma fibrinogen and forced expiratory volume in 1 s (FEV(1)), and assessed prospectively COPD hospitalizations in 8,955 adults from the Danish general population. Smokers with plasma fibrinogen in the upper and middle tertile (> 3.3 and 2.7-3.3 g/L) had 7% (95% confidence interval [CI]: 5-8%) and 2% (0-3%) lower percentage predicted FEV(1) than smokers with fibrinogen in the lower tertile (< 2.7 g/L). The equivalent decreases in nonsmokers were 6% (4-7%) and 0% (-1-2%), respectively. Individuals with plasma fibrinogen in the upper and middle tertile had COPD hospitalization rates of 93 and 60 compared with 52 per 10,000 person-years in individuals with fibrinogen in the lower tertile (log-rank: p < 0.001 and p = 0.31). After adjusting for age, body mass index, sex, pack-years, and recent respiratory infections, relative risks for COPD hospitalization were 1.7 (95% CI: 1.1-2.6) and 1.4 (0.9-2.1) in individuals with fibrinogen in the upper and middle versus lower tertile. In conclusion, elevated plasma fibrinogen was associated with reduced FEV(1) and increased risk of COPD. This could not be explained by smoking alone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587987     DOI: 10.1164/ajrccm.164.6.2010067

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  68 in total

Review 1.  [Comorbidities of COPD].

Authors:  H Watz; H Magnussen
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

2.  Systemic inflammation and progression of COPD.

Authors:  Jørgen Vestbo
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

Review 3.  Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials.

Authors:  Prescott G Woodruff
Journal:  Proc Am Thorac Soc       Date:  2011-08

4.  The Importance of Neutrophil-to-Lymphocyte Ratio in Chronic Obstructive Pulmonary Disease.

Authors:  Erdal İn; Mutlu Kuluöztürk; Önsel Öner; Figen Deveci
Journal:  Turk Thorac J       Date:  2016-04-01

Review 5.  Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Omar A Minai; Zab Mosenifar
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 6.  Perinatal stress and early life programming of lung structure and function.

Authors:  Rosalind J Wright
Journal:  Biol Psychol       Date:  2010-01-18       Impact factor: 3.251

7.  Systemic inflammation in chronic obstructive pulmonary disease: a population-based study.

Authors:  Francisco Garcia-Rio; Marc Miravitlles; Joan B Soriano; Luis Muñoz; Enric Duran-Tauleria; Guadalupe Sánchez; Víctor Sobradillo; Julio Ancochea
Journal:  Respir Res       Date:  2010-05-25

8.  The association between blood coagulation activity and lung function: a population-based study.

Authors:  Andrew W Fogarty; Sarah A Lewis; Tricia M McKeever; Gordon D O Lowe; Lorna Clark; John Britton
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

9.  Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study.

Authors:  Rodolfo J Dennis; Dario Maldonado; Maria X Rojas; Pablo Aschner; Martin Rondón; Laura Charry; Alejandro Casas
Journal:  BMC Pulm Med       Date:  2010-07-26       Impact factor: 3.317

Review 10.  Markers of early disease and prognosis in COPD.

Authors:  Morten Dahl; Børge G Nordestgaard
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.